Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $19.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE